RecruitingPhase 2NCT07400965
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Studying Medullary sponge kidney
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Glaukos Corporation
- Principal Investigator
- Study Director, MDGlaukos Corporation
- Intervention
- GLK-321 low dose BID(drug)
- Enrollment
- 250 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Glaukos Clinical Study Site, Newport Beach, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07400965 on ClinicalTrials.govOther trials for Medullary sponge kidney
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07489131Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaAlvotech Swiss AG
- RECRUITINGPHASE2NCT07441642A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNovartis Pharmaceuticals
- ENROLLING BY INVITATIONPHASE2NCT07395986A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
- RECRUITINGPHASE3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc.
- RECRUITINGPHASE2NCT07128628A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseBausch & Lomb Incorporated
- RECRUITINGPHASE3NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc
- RECRUITINGPHASE3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics
- RECRUITINGPHASE3NCT06996080A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLEKodiak Sciences Inc